Novel Therapeutic Technologies
Novel Therapeutic Technology develops practical drug delivery systems
About Novel Therapeutic Technologies
Novel Therapeutic Technologies (NTT), Inc. was a biopharmaceutical firm established in 2003 with its headquarters in Wilmington, Delaware, and an operational presence in Israel. The company was steered by CEO Yitzhak Turkeltaub. NTT operated within the drug delivery sector, focusing on enhancing the application and efficacy of topical medications for pharmaceutical partners.
The core of the company's intellectual property was its Ethosome technology, a non-invasive transdermal delivery system. This platform utilized soft, malleable vesicles composed of phospholipids and a high concentration of ethanol to carry active pharmaceutical ingredients through the skin's outer layer. The primary benefit of this approach was to significantly increase the penetration of drugs into the skin, thereby boosting therapeutic effectiveness while potentially lowering required dosages and reducing side effects. The technology was versatile, capable of encapsulating both lipophilic and hydrophilic molecules for a wide range of potential applications, including antibiotics and anti-inflammatory drugs.
NTT's business model involved collaborating with pharmaceutical companies to reformulate their existing drugs using the Ethosome system, aiming to create enhanced, patentable products. In addition to these partnerships, the company also developed its own private label offerings, including an anti-cellulite product that leveraged the Ethosome platform. The company secured a substantial Series D funding round of $75 million in late 2011, a significant capital injection intended to advance its development programs. Despite this funding, corporate activity appears to have ceased in the following years, and the company is now reported as being out of business.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Dec 2011 | $75M | $525M | Undisclosed | — |
Growth signals
Latest recorded traffic for Novel Therapeutic Technologies is 0 monthly website visits. Novel Therapeutic Technologies's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Novel Therapeutic Technologies in the Wilmington ecosystem
The Novel Therapeutic Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novel Therapeutic Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novel Therapeutic Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









